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Abstract. Constitutive activation of the signal transducer 
and activator of transcription 3 (STAT3) signaling pathway 
possesses confirmed oncogenic potential in oral squamous cell 
carcinoma (OSCC). Crosstalk with other molecular pathways 
contributes to STAT3 regulation in cancer. The effects of 
mitogen-activated protein kinases (MAPKs) and particularly 
extracellular signal-regulated kinase 1/2 (Erk1/2) on STAT3 
signaling in OSCC have not been thoroughly investigated. The 
present study examined the effects of Erk1/2 modulation on 
STAT3 signaling and cell growth in OSCC cells. Constitutive 
expression levels of phosphorylated (tyrosine and serine) and 
total STAT3, Erk1/2 and cyclin D1 were assessed in OSCC cell 
lines. Erk1/2 modulation was achieved by pharmacological 
agents; siRNA silencing against Erk1/2 was also performed. 
Cell proliferation and viability were assessed. Erk1/2 inhibi-
tion with either U0126 treatment or specific siRNA silencing 
resulted in decreases in p-ser STAT3 and cyclin D1 levels and 
increases in p-tyr STAT3 in OSCC cells. Moreover, Erk1/2 
inhibition resulted in a dose-dependent reduction in OSCC 
cell growth and viability. Erk1/2 induction had the opposite 
effects. Taken together, these results are supportive of an 
active crosstalk between the oncogenic Erk1/2 and STAT3 
pathways in OSCC, the significance of which requires further 
investigation.
Introduction
Oral cancer is the sixth most common cancer in the world and 
the incidence of new cases indicates a continuing rise in devel-
oping countries (1). Several genetic and epigenetic alterations 
underlie the progressive acquisition of a malignant phenotype 
in head and neck squamous cell carcinoma (HNSCC) (2). 
The molecular dissection of aberrant signaling networks, 
including EGFR, Ras, NF-κB, Wnt/β-catenin, TGF-β, and 
PI3K-AKT-mTOR signaling pathways, has increased our 
understanding of the basic mechanisms controlling HNSCC 
progression (2,3).
Signal transducer and activator of transcription (STAT) 
proteins constitute a family of transcription factors, which 
exist in the cell as latent cytoplasmic transcription factors and 
become activated in response to stimulation by cytokines and 
growth factors (4,5). Once bound to their receptors, STATs 
become phosphorylated, they dissociate from the receptor and 
form homo- or heterodimers (4-7). STAT dimers then translo-
cate to the nucleus, where they interact with the promoters of 
target genes, thus regulating transcription (4-7).
Phosphorylation of STAT molecules on a tyrosine residue 
is the first critical event for their activation and has been 
convincingly shown to correlate with STAT DNA binding and 
transcriptional activity (4-7). In contrast, STAT serine phos-
phorylation, which may also occur in response to growth factor 
and cytokine stimulation, has been associated mainly with 
negative regulation of STAT activity (8-11). Other authors have 
indicated that STAT1 and STAT3 are often phosphorylated in 
serine residues, resulting in further STAT activation (12).
STAT signaling has been found to be involved in oncogen-
esis (13,14). STAT3 persistent activation has been convincingly 
shown to contribute to a malignant phenotype (13). Constitutive 
activation of STAT3 has been associated with tumorigenesis 
in various types of human cancer by stimulating specific 
target genes that enhance cell proliferation and prevent apop-
tosis (13-15).
There is compelling evidence that STAT3 constitutive 
activation, mainly associated with aberrant TGF-α/EGFR 
signaling, is linked to HNSCC development and growth 
(2,14-18). Previous findings suggested the existence of EGFR-
independent STAT oncogenic properties in HNSCC, including 
autocrine/paracrine cytokine (IL-6, IL-10 or IL-22) stimulation 
or signaling through 7 nicotinic and erythropoietin receptor 
pathways (17,19-23). Cytokine receptors are constitutively 
associated with members of the Janus kinase (JAK) family of 
protein tyrosine kinases, whereas growth factor receptors have 
intrinsic tyrosine kinase activity (5).
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Mitogen-activated protein kinase (MAPK) pathways are 
evolutionarily conserved kinase modules that link extracel-
lular signals to the machinery that controls fundamental 
cellular processes such as growth, proliferation, differen-
tiation, migration and apoptosis (24). MAPKs phosphorylate 
serine and threonine residues of specific target proteins (25). 
MAPKs are classified into three major subfamilies, including 
extracellular signal-regulated kinases (ERKs), p38 MAPKs, 
and c-Jun NH2-terminal kinases (JNKs) (25-27).
Previous studies supported an association between activa-
tion of specific members of the MAPK family and negative 
regulation of STAT3 signaling in various cell types (8,28-34). 
Chung et al showed that ERKs phosphorylate STAT3 on 
serine 727 (Ser727) in vitro and in vivo, while inhibiting 
STAT3 tyrosine phosphorylation (8). Similarly, Jain et al 
confirmed that ERKs induce STAT3 serine phosphorylation 
and suppress STAT3 tyrosine phosphorylation, DNA binding 
and transcriptional activity induced by Src or Jak-2 (28). 
Moreover, Sengupta et al provided evidence that activated 
ERKs induce a rapid downregulation of IL-6-mediated 
STAT3 signaling through inhibition of the upstream JAK 
kinases in several cell lines (29). Recently, Gough et al 
found that the MEK-ERK pathway is required for activated 
Ras-induced phosphorylation of mitochondrial STAT3 on 
Ser727, an important process during cellular transformation 
(35). Also, xue et al suggested that treatment of human lung 
adenocarcinoma cells with RY10-4 affected Bcl-2 family 
members, caspases, MMPs, TIMPs expression and ROS 
production by inhibiting STAT3 activities through ERK and 
p38 pathways (36). Finally, Lee et al found that blockade 
of MEK1/2-Erk1/2-RSK2 signaling by silybin resulted in a 
reduced activation of NF-κB, activator protein-1, and STAT3 
in melanoma cells (37). Collectively, there is compelling 
evidence to suggest that MAPK, especially ERK, activation 
has an inhibitory effect on STAT3 signaling, manifested 
by downregulation of STAT3 tyrosine phosphorylation and 
induction of STAT3 serine phosphorylation, in various cell 
types including cancer cells.
The aim of the present investigation was to evaluate whether 
oncogenic constitutive STAT3 signaling in oral squamous 
cell carcinoma (OSCC) cells can be modulated by regulation 
of specific MAPKs. The expression and activation status of 
STAT3 and Erk1/2 in HNSCC cell lines were recorded and the 
effects of selective Erk1/2 inhibition or activation on STAT3 
signaling and cellular proliferation were monitored, in an 
effort to elucidate important molecular aspects of oral cancer 
with potential therapeutic implications.
Materials and methods
Cell lines and cell culture. Experiments were performed using 
established cell lines of human HNSCC (SCC9 and SCC25) 
obtained from the American Type Culture Collection (ATCC; 
Manassas, vA, USA). Cells were cultured in a 1:1 mixture 
of Ham's F12 and DMEM containing 10% fetal bovine 
serum (FBS), 100 units of penicillin, and 400 ng/ml hydrocor-
tisone (Sigma Chemical Co., St. Louis, MO, USA) at 37˚C in a 
5% CO2 air atmosphere. Cells were subcultured by disaggrega-
tion with trypsin (0.1%)-EDTA (0.01%) in phosphate-buffered 
saline (PBS) at pH 7.5.
Selective inhibition of Erk1/2. Cells were plated in 6-well 
plates at a density of 5x104 cells/well and were allowed to 
grow to 80% confluency. Then, they were treated either with 
the vehicle alone (DMSO at a maximum concentration of 
0.1%) or with the selective MAPK (Erk1/2) inhibitor U0126 
(Calbiochem, San Diego, CA, USA) at concentrations of 20 
and 50 µM for 24 h.
Selective induction of Erk1/2 MAPK. Cells were plated in 
6-well plates at a density of 2x105 cells/well and were allowed 
to grow to 80% confluency. They were then treated either with 
the vehicle alone (DMSO at a maximum concentration of 
0.1%) or with the selective MAPK (Mek1/2) inducer (ProSpec, 
Israel) at concentrations of 2 and 5 µM for 48 h.
siRNA transfection. The human Erk1 and Erk2 specific 
siRNAs were based on NCBI Reference Sequences (GenBank: 
Erk1: NM_002746 and Erk2: NM_002745). Erk1/2 siRNA 
and scrambled control siRNA (siControl) were purchased 
from Qiagen. All siRNA transfections were performed 
using Lipofectamine 2000 (Invitrogen), according to the 
manufacturer's protocol, with final siRNA concentrations of 
1 and 2.5 µM. OSCC cells were grown to mid-log phase and 
were transiently transfected (2x106 cells) with 50 µg of the 
empty vector or siRNA using Nucleofector reagents (Amaxa 
Biosystems, Gaithersburg, MD, USA). Cells were collected at 
48 h and whole lysates were analyzed by western blotting.
Western blot experiments. Cells were washed twice with 
ice-cold PBS, followed by lysis with radioimmunopre-
cipitation assay buffer (50 mM Tris pH 7.4, 150 mM NaCl, 
1% Triton x-100, 1% deoxycholic acid, sodium salt, 0.1% 
sodium dodecyl sulfate, 100 mg/ml phenylmethylsulfonyl 
fluoride, 1 mg/ml aprotinin, 1 mM dichlorodiphenyltrichlo-
roethane and 1 mM sodium orthovanadate) for 10 min at 
4˚C. The wells were scraped, and recovered cell products 
were centrifuged at 40,000 x g for 15 min at 4˚C. Recovered 
proteins were measured and equalized using Bio-Rad Protein 
Assay (Bio-Rad Laboratories, Richmond, CA, USA) as per the 
manufacturer's instructions.
Western blotting was performed using antibodies against: 
total STAT3, phospho-STAT3 (Tyr705), phospho-STAT3 
(Ser727), total p44/42(Erk1/2) (Cell Signaling, Beverly, MA, 
USA), phospho-Erk1/2 ΜAPK, (Upstate, Charlottesville, 
vA, USA), cyclin D1 (Cell Signaling) and β-actin (Sigma 
Chemical).
Cell proliferation and viability. Cells were counted with a 
hemocytometer under inverted microscope. Cell viability after 
treatment was determined by the trypan blue dye exclusion 
test 24 h after each treatment. All assays were performed in 
quadruplicate and results are reported as the mean ± SD.
Results
Effects of U0126 inhibitor on Erk1/2, STAT3 and cyclin D1 
protein expression and activation. The expression and acti-
vation status of Erk1/2 in OSCC cells was examined first. 
According to western blotting experiments, Erk1/2 (p42/44) 
total and phosphorylated (activated) protein levels were 
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detected in both OSCC cell lines tested (SCC9 and SCC25). 
Total, tyrosine phosphorylated (p-tyr) and serine phosphory-
lated (p-ser) STAT3, as well cyclin D1 protein levels were also 
observed in both cell lines (Fig. 1).
The effectiveness of Erk1/2 inhibition was then assessed. 
Treatment of oral SCC25 cells with the Erk1/2 inhibitor 
U0126 for 24 h resulted in inhibition of Erk1/2 phosphoryla-
tion, which was more pronounced at the highest concentration 
used (50 µM). A decrease in total Erk1/2 protein expression 
levels following 20 or 50 µM of U0126 treatment was also 
noted in SCC25 cells. On the other hand, U0126 treatment of 
oral SCC9 cells caused less notable effects on Erk1/2 protein 
expression and phosphorylation with decreases observed only 
at the highest concentration (50 µM) (Fig. 1).
The effectiveness of Erk1/2 inhibition on STAT3 protein 
expression and activation levels was also examined. In oral 
SCC25 cells, a significant reduction of p-ser STAT3 was 
detected after 24 h of treatment with 20 or 50 µM of U0126; 
in contrast, p-tyr STAT3 levels were not significantly affected. 
On the other hand, treatment of SCC9 cells with U0126 led 
to a decrease of p-ser STAT3 only when a concentration of 
50 µM was used, along with a moderate increase in p-tyr 
STAT3 levels. Total STAT3 levels were not affected by U0126 
treatment in either cell line (Fig. 1).
Moreover, western blot analysis demonstrated that inhibi-
tion of Erk1/2 was associated with decreased levels of cyclin D1 
expression in a dose-dependent manner in both cell lines. In 
contrast, the levels of actin remained stable throughout the 
treatment, indicating that the observed effects on the afore-
mentioned proteins were not caused by a nonspecific reduction 
of protein expression (Fig. 1).
Hence, Erk1/2 inhibition by U0126 treatment was more 
potent in oral SCC25 cells and was associated with a decrease 
in p-ser STAT3 and cyclin D1 levels without affecting p-tyr 
STAT3 levels. In contrast, U0126 treatment of oral SCC9 cells 
appeared to be less effective in reducing Erk1/2 phosphorylation; 
nonetheless, it induced decreases in p-ser STAT3 levels and 
cyclin D1 protein expression as well as increases in p-tyr 
STAT3 levels at the highest concentration used.
Effects of U0126 inhibitor on cell growth and viability. 
Treatment with U0126 for 24 h resulted in a statistically 
significant (P<0.05) dose-dependent reduction in cell growth 
(absolute number of cells) and cell viability (number of viable 
cells) in both cell lines tested. The reduction appears to be 
more prominent in the oral SCC9 cell line (Fig. 2).
Effects of Erk1/2 siRNA silencing on STAT3 and cyclin D1 
protein expression and activation. In order to corroborate the 
results from the pharmacological inhibition of Erk1/2, specific 
inhibition was performed by siRNA-targeting of Erk1/2 in 
both cell lines. Following 48 h of transfection, western blotting 
revealed that si-RNA against Erk1/2 efficiently silenced Erk1/2 
causing dose-dependent decreases in total and phosphorylated 
p42/44 Erk1/2 protein levels compared to control-transfected 
cells in both cell lines (Fig. 3).
Decreases in Erk1/2 protein expression and phosphoryla-
tion correlated with a decrease in p-ser STAT3 in both cell 
lines, after 48 h of treatment with 2.5 µM of specific siRNA 
against Erk1/2. Regarding STAT3 tyrosine phosphorylation, 
an upregulation of p-tyr-STAT3 protein levels was detected, 
particularly at the highest concentration, in oral SCC9 cells. 
On the other hand, siRNA treatment against Erk1/2 did not 
appear to cause any observable change in p-tyr-STAT3 levels 
Figure 2. Effect of U0126 on cell growth and viability. Treatment of cells 
with Erk1/2 inhibitor U0126 affected both cell viability and absolute number 
of living cells. The reduction appeared to be more prominent in the SCC9 cell 
line. Columns, average of four determinations; bars, SD. 
Figure 1. Effect of U0126 inhibitor on STAT3 phosphorylation and cellular 
activity. Treatment of cells with U0126 for 24 h had a slight decreasing 
effect on total Erk1/2(p42/44) levels in SCC25, while, as expected, it led 
to reduced levels of phospho-Erk1/2 more pronounced at the highest con-
centration. Selective inhibition of ERK also resulted in downregulation of 
phospho-STAT3 (Ser727). Inhibition of ERK did not affect the constitu-
tive levels of phospho-STAT3 (Y705) in SCC25. In contrast, in the SCC9 
cell line, STAT3 phosphorylation in Tyr705 presented moderate increase. 
Cyclin D1 levels decreased in both cell lines in a dose-dependent manner. 
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in oral SCC25 cells. Total STAT3 protein levels were not 
affected in either cell line (Fig. 3).
Furthermore, western blot analysis demonstrated that 
silencing of Erk1/2 was associated with substantially decreased 
levels of cyclin D1 protein expression in a dose-dependent 
manner in both cell lines. Finally, the levels of actin remained 
stable (Fig. 3). Therefore, specific silencing of Erk1/2 resulted 
in a decrease in p-ser STAT3 and cyclin D1 levels in both 
cell lines and an increase in p-tyr-STAT3, particularly in oral 
SCC9 cells.
Effects of silencing Erk1/2 on cell growth and viability. Similar 
to the effects of chemical inhibition with U0126, 48 h of treat-
ment with siRNA against Erk1/2 resulted in a dose-dependent 
reduction in cell growth and cell viability in both cell lines 
(P<0.05) (Fig. 4).
Effects of Erk1/2 induction on STAT3 and cyclin D1 protein 
expression and activation. In order to further investigate the 
significance of Erk1/2 for STAT3 and cyclin D1 modulation, 
pharmacological induction of Erk1/2 using active MEK1/2 
was performed. Treatment of cells with selective MEK1/2 
inducer efficiently upregulated phosphorylated Erk1/2 levels in 
a dose-dependent manner in both cell lines without affecting 
total Erk1/2 levels, as expected (Fig. 5).
Treatment of both cell lines with Erk1/2 inducer for 48 h 
resulted in significant induction of STAT3 phosphorylation on 
Ser727, especially at a concentration of 5 µm/ml. In contrast, 
p-tyr-STAT3 levels appeared to decrease after treatment with 
active MEK1/2. Total STAT3 levels were not affected by 
Erk1/2 induction in either cell line (Fig. 5).
With regards to cyclin D1, active MEK1/2 treatment of 
both cell lines for 48 h caused an upregulation in cyclin D1 
expression levels, particularly at the higher concentration. 
Finally, actin protein levels remained stable throughout treat-
ment (Fig. 5). Thus, Erk1/2 induction caused upregulation 
of p-ser STAT3 and cyclin D1 levels in both cell lines and a 
decrease in p-tyr-STAT3.
Effects of Erk1/2 induction on cell growth and viability. 
Active MEK1/2 treatment at the highest concentration for 
48 h resulted in a significant dose-dependent increase in cell 
growth, which was more prominent in the oral SCC25 cell 
line (P<0.05). On the contrary, treatment of cells with active 
MEK1/2 for 48 h did not appear to induce notable changes in 
cell viability in either cell line (Fig. 6).
Figure 5. Effect of Erk1/2 induction on STAT3 phosphorylation and cel-
lular activity. Induction of Erk1/2 with active MEK1/2 for 48 h successfully 
enhanced phospho-Erk1/2. Furthermore, induction of ERK resulted in 
upregulation of phospho-STAT3 (Ser727) and in slight downregulation of 
STAT3 tyrosine phosphorylation. Treatment of both cell lines for 48 h also 
caused a slight upregulation in cyclin D1 expression levels. 
Figure 4. Effect of silencing Erk1/2 on cell growth and viability. Treatment of 
cells with siErk1/2 decreased the absolute number of living cells and reduced 
the percentage of cell viability levels in both cell lines. Columns, average of 
four determinations; bars, SD. 
Figure 3. Effect of Erk1/2 silencing (siRNA) on STAT3 phosphorylation 
and cellular activity. Αfter siRNA transfection (48 h), western blotting 
revealed that the siErk1/2 inhibited total protein expression compared with 
control transfection experiments. Moreover, the level of phospho-Erk1/2 
was markedly reduced in these cells in a dose-dependent manner. The 
decrease in Erk1/2 expression/phosphorylation correlated with a decrease 
of phospho-STAT3 (Ser727) and cyclin D1 expression while p-tyr-STAT3 
protein levels were detected, especially at the highest concentration, in oral 
SCC9 cells.
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Discussion
The oncogenic role of MAPK signaling pathway has been the 
focus of numerous studies indicating that aberrant MAPK 
expression alters differentiation and deregulates proliferation 
and apoptosis in several types of cancer (38,39). In particular, 
ERK is a member of an oncogenic pathway activated by the 
upstream oncoproteins Ras and Raf (24,40). Upon activation, 
Erk1/2 phosphorylates either cytoplasmic downstream targets, 
including p90 ribosomal S6 kinase, or nuclear substrates (24,41). 
In the nucleus, ERK phosphorylates an array of targets, 
including transcription factors and the family of mitogen and 
stress-activated protein kinases (MSKs) (42). ERK nuclear 
targets also include the Ternary Complex Factor (TCF), which 
plays a crucial role in enhancing expression of the immediate 
early genes, such as c-Fos and c-Myc (39,43).
The significance of the MEK/ERK pathway has been 
shown in various types of cancer, such as liver, prostate 
and malignant melanoma cancer cell growth in vitro and 
in vivo (44-46). For example, knockdown of serine/threonine 
kinase Mirk/Dyrk1B by siRNA in either ovarian cancer or 
non-small cell lung cancer (NSCLC) cells led to upregulated 
activation of c-Raf-MEK-ERK, followed by increased growth 
rate (47). Induction of anti-apoptotic proteins, such as Bcl2, 
Bclxl and inhibition of pro-apoptotic factors, including Bad, 
has been correlated with the oncogenic potential of ERK 
activity (48).
Deregulation of ERK has also been described in HNSCC 
and various studies have suggested that ERK inhibition 
correlates with reduced proliferation and induced apoptosis 
in OSCC (49,50). Wang et al suggested that overexpres-
sion of activated Erk1/2 and cyclin D1 might be related to 
cell cycle regulation and cell proliferation in OSCC (51). 
Bancroft et al (52) showed the involvement of Erk1/2 in 
AP-1 and NF-κB induction of vEGF expression in OSCC 
cell lines SCC9 and SCC11, and Duvvuri et al (53) found 
that overexpression of Erk1/2, induced by receptor-activated 
calcium-dependent chloride channel (TMEM16A), is associ-
ated with enhanced cell proliferation in HNSCC. Recently, 
Li et al demonstrated that knockdown of kinase suppressor of 
Ras 1 and suppression of the Raf-MEK-ERK pathway reduced 
proliferation and induced apoptosis in OSCC cells (54).
In agreement with the aforementioned findings, our results 
are in support of the oncogenic role of ERK in oral cancer. 
In the present study, possible effects of ERK modulation on 
OSCC cell proliferation and viability were assessed. In partic-
ular, Erk1/2 inhibition caused a dose-dependent decrease in 
the absolute number of living cells along with downregulation 
of cyclin D1 levels in both OSCC cell lines tested. These find-
ings corroborate previous studies that demonstrated negative 
regulation of cell growth and cyclin D1 levels following Erk1/2 
inhibition by means of U0126 treatment (44,47,55,56).
In our study, selective siRNA Erk1/2 inhibition induced 
similar results to those of Erk1/2 pharmacological inhibi-
tion in a dose-dependent manner in both cell lines, followed 
by a corresponding decrease in the absolute number of 
living cells and cell viability levels. Using similar siRNA 
techniques, Bessard et al underlined the crucial role of the 
MEK/ERK pathway in liver cancer cell growth in vitro and 
in vivo demonstrating that RNAi-mediated Erk2 knockdown 
inhibits tumor cell growth (44). Similarly, Si et al showed that 
downregulation of Erk1/2 by siRNA inhibited the growth 
and invasion of human osteosarcoma cells, and found that 
the knockdown of Erk1/2 made cancer cells more sensi-
tive to cisplatin treatment (57). Moreover, Dumesic et al 
reported that combined siRNA-induced knockdown of Erk1/2 
caused epidermal hypoplasia and hypoproliferation without 
disrupting differentiation in human epidermis (58). Finally, 
Duvvuri et al found that genetic inactivation of Erk1/2 using 
siRNA abrogated the Erk1/2 mediated growth effects of 
TMEM16A in HNSCC (53).
Furthermore, we demonstrated that pharmacological 
induction of Erk1/2 appears to have the opposite effects. 
Notably, the increase in absolute cell number is accompanied 
by a relative increase in cyclin D1. In agreement, Gao et al 
suggested that activation of the c-Raf-MEK-Erk1/2 pathway 
leads to subsequent increase in cell cycle proteins (cyclin D1, 
p27kip1), accompanied by an increased growth rate and transi-
tion of cells from G0/G1 into the S phase of the cell cycle in 
both ovarian and non-small cell lung cancer (47). Similarly, 
Wang et al indicated that overexpression of activated Erk1/2 
Figure 6. Effect of Erk1/2 induction on cell growth and viability. Induction 
of Erk1/2 with selective MEK1/2 inducer affected absolute number of living 
cells and led to cell growth, particularly at the higher concentration in both 
cell lines. Treatment of cells with active MEK1/2 for 48 h did not appear to 
cause any change in cell viability in either cell line. Columns, average of four 
determinations; bars, SD. 
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and cyclin D1 proteins are involved in oral tongue carcinogen-
esis (51). Finally, Judd et al (59) reported that MEK1 activation 
enhances CD44 expression and promotes aggressiveness in 
HNSCC, while Katada et al (60) and Zuo et al (61) suggested 
that Erk1/2 activation correlates with increased cell migration 
and invasion in HNSCC.
A number of findings indicate that STAT3 is constitutively 
activated and participates in the regulation of cell prolifera-
tion, differentiation and apoptosis in HNSCC (17,18). Aberrant 
STAT3 activation, manifested by increases in STAT3 tyro-
sine phosphorylation, is considered as a potent promoter of 
HNSCC initiation and progression, thereby inhibition of 
STAT3 has been identified as a potential therapeutic target 
for the treatment of HNSCC (16,18,62). STAT3 constitutive 
activation in HNSCC is driven by a number of upstream 
signal transduction pathways. Ligand-induced stimulation of 
the receptor results in phosphorylation of tyrosine residues 
within the receptor, which is the first critical event for their 
activation and has been shown to correlate with STAT DNA 
binding and transcriptional activity (4,5,7-9). The oncogenic 
potential of STAT3 depends mainly on the phosphorylation 
status of Tyr705 whereas the role of STAT3 serine phos-
phorylation is more controversial (7). There are several lines 
of evidence supporting a negative impact of Ser727 residue 
phosphorylation on STAT3 activity. Previous studies have 
demonstrated that Ser727 phosphorylation negatively regu-
lates STAT3 tyrosine phosphorylation, which is required 
for dimer formation and the subsequent nuclear transloca-
tion and transcriptional activity (8). Similarly, Decker and 
Kovarik proposed that STAT3 phosphorylation on Ser727 
either inhibits tyrosine phosphorylation or increases tyrosine 
dephosphorylation (9). A negative relationship between STAT3 
serine and tyrosine phosphorylation has also been suggested 
by venkatasubbarao et al (10) and Wakahara et al (63), who 
described that phospho-Ser727 determines the duration of 
STAT3 activity by enhancing dephosphorylation of phospho-
Tyr705 largely through TC45 phosphatase.
However, other investigators suggested that STAT3 serine 
phosphorylation is associated with increased nuclear translo-
cation and serves to maximize transcriptional activity (6,64). 
Hazan-Halevy et al reported that constitutive phosphorylation 
of STAT3 on Ser727 residues is a critical event in chronic 
lymphocytic leukemia (CLL) and may serve as a potent 
therapeutic target (64). Miyakoshi et al showed that FBS 
treatment of mouse hepatic carcinoma cells induced STAT3 
phosphorylation on Ser727 via MAPK activation, followed 
by STAT3 nuclear translocation and cell proliferation (66). 
In contrast, IL-6 treatment induced STAT3 phosphoryla-
tion on Tyr705 phosphorylation through JAK activation 
without increasing STAT3 nuclear translocation and cell 
proliferation. Sakaguchi et al investigated the oncogenic 
role of Ser727 STAT3 in melanoma cells and suggested that 
constitutive Ser727 phosphorylation, partially mediated by 
the B-Raf-MEK-Erk1/2 pathway, has a role in the regulation 
of cell survival activity and nuclear translocation of STAT3 
in melanocytes (65). Moreover, Gough et al proposed that the 
MEK-ERK pathway is required for activated Ras-induced 
phosphorylation of STAT3 on Ser727 and that mitochondrial 
STAT3 is one of the critical substrates of the Ras-MEK-ERK-
axis during cellular transformation (35).
One of the major downstream signaling routes of MAPKs 
are STAT proteins and MAPKs have been implicated in the 
regulation of STAT proteins through crosstalk signaling (9).
Considering the significance of STAT3 and ERK signaling 
in several types of cancer, the possibility of a crosstalk between 
these two major oncogenic pathways in oral cancer was explored 
in the present study. In particular, changes in the expres-
sion and activation status of Erk1/2 MAPK and their effect 
on STAT3 tyrosine and/or serine phosphorylation and total 
STAT3 levels in OSCC cell lines were investigated. Chemical 
inhibition (via U0126) or selective targeting (via siRNA) of 
Erk1/2 MAPK downregulated STAT3 serine phosphoryla-
tion in both cell lines used; in addition, a moderate increase 
in STAT3 tyrosine (Y705) phosphorylation was observed 
in oral SCC9 cells. In contrast, induction of ERK in OSCC 
cells resulted in upregulation of STAT3 serine phosphoryla-
tion and downregulation of STAT3 tyrosine phosphorylation. 
Previous studies suggested that a crosstalk exists between 
ERK and STAT3, indicating that ERK either induces Ser727 
phosphorylation (8,28,35) or downregulates IL-6-mediated 
STAT3 signaling (29). In pancreatic cancer cells, ERK acti-
vation has been associated with STAT3 negative regulation 
manifested by decreased tyrosine phosphorylation levels (10). 
Similar results were obtained by Tkach et al, who found that 
U0126 suppresses phosphorylation of STAT3 on Ser727 in 
breast cancer cells (33). In addition, Wierenga et al, indicated 
that U0126 abrogated the EPO-mediated STAT3 Ser727 phos-
phorylation without an effect on tyrosine phosphorylation in 
erythroid cells (67). Nelson et al found that the combination of 
nifuroxazide and U0126 inhibits STAT3 tyrosine phosphory-
lation in multiple myeloma cells (68). Furthermore, Chen et al 
reported that Erk1/2 activation phosphorylates STAT3 on 
Ser727 and regulates cell proliferation in human bladder 
cancer cells (34). On the other hand, Sumimoto et al reported 
that U0126 inhibits ERK phosphorylation, but not STAT3 
phosphorylation on Ser727 or Tyr705 residues in human mela-
noma cells (69). It can be hypothesized that the significance of 
Erk1/2 and STAT3 crosstalk differs according to the cancer 
cell types studied.
In summary, our data are supportive of the oncogenic 
potential of Erk1/2 in OSCC, which appears to contribute to 
cell proliferation. It is possible that pharmacologic inhibi-
tion of Erk1/2 activity or targeting Erk1/2 genes by gene 
therapy may offer an alternative strategy for the treatment of 
patients with OSCC. On the other hand, the oncogenic STAT3 
constitutive signaling in OSCC cells appears to be negatively 
regulated by Erk1/2. The Erk1/2-STAT3 crosstalk appears to 
involve mainly ERK-induced upregulation of STAT3 Ser727 
phosphorylation while Tyr705 phosphorylation does not 
exhibit major changes. It is possible that the role of Erk1/2 in 
STAT3 modulation varies according to the type and status of 
the cells studied, indicating the need to identify the role of 
MAPK activation in relation to STAT3 signaling in specific 
cell types.
Acknowledgements
This study was co-financed by the European Union (Euro pean 
Social Fund - ESF) and Greek national funds through the 
Operational Program ‘Education and Lifelong Learning’ of the 
ONCOLOGY REPORTS  32:  2175-2182,  2014 2181
National Strategic Reference Framework (NSRF) - Research 
Funding Program: Heracleitus II. Investing in knowledge 
society through the European Social Fund.
References
 1. Curado MP and Hashibe M: Recent changes in the epidemiology 
of head and neck cancer. Curr Opin Oncol 21: 194-200, 2009.
 2. Molinolo AA, Amornphimoltham P, Squarize CH, et al: 
Dysregulated molecular networks in head and neck carcino-
genesis. Oral Oncol 45: 324-334, 2009.
 3. Choi S and Myers JN: Molecular pathogenesis of oral squamous 
cell carcinoma: implications for therapy. J Dent Res 87: 14-32, 
2008.
 4. Bromberg J and Darnell JE Jr: The role of STATs in transcrip-
tional control and their impact on cellular function. Oncogene 19: 
2468-2473, 2000.
 5. Rane SG and Reddy EP: Janus kinases: components of multiple 
signaling pathways. Oncogene 19: 5662-5679, 2000.
 6. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al: Signal 
transducer and activator of transcription-3, inflammation, and 
cancer: how intimate is the relationship? Ann NY Acad Sci 1171: 
59-76, 2009.
 7. Reich NC and Liu L: Tracking STAT nuclear traffic. Nat Rev 
Immunol 6: 602-612, 2006.
 8. Chung J, Uchida E, Grammer TC and Blenis J: STAT3 serine 
phosphorylation by ERK-dependent and -independent pathways 
negatively modulates its tyrosine phosphorylation. Mol Cell 
Biol 17: 6508-6516, 1997.
 9. Decker T and Kovarik P: Serine phosphorylation of STATs. 
Oncogene 19: 2628-2637, 2000.
10. venkatasubbarao K, Choudary A and Freeman JW: Farnesyl trans-
ferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) 
phosphorylation in human pancreatic cancer cell lines require 
extracellular signal-regulated kinases. Cancer Res 65: 2861-2871, 
2005.
11. Lim CP and Cao x: Serine phosphorylation and negative regu-
lation of STAT3 by JNK. J Biol Chem 274: 31055-31061, 1999.
12. O'Shea JJ, Gadina M and Schreiber RD: Cytokine signaling in 
2002: new surprises in the Jak/Stat pathway. Cell 109: S121-S131, 
2002.
13. Bromberg J: Stat proteins and oncogenesis. J Clin Invest 109: 
1139-1142, 2002.
14. Song JI and Grandis JR: STAT signaling in head and neck cancer. 
Oncogene 19: 2489-2495, 2000.
15. Grandis JR, Drenning SD, Zeng Q, et al: Constitutive acti-
vation of Stat3 signaling abrogates apoptosis in squamous cell 
carcinogenesis in vivo. Proc Natl Acad Sci USA 97: 4227-4232, 
2000.
16. Nikitakis NG, Siavash H and Sauk JJ: Targeting the STAT 
pathway in head and neck cancer: recent advances and future 
prospects. Curr Cancer Drug Targets 4: 637-651, 2004.
17. Kijima T, Niwa H, Steinman RA, et al: STAT3 activation 
abrogates growth factor dependence and contributes to head 
and neck squamous cell carcinoma tumor growth in vivo. Cell 
Growth Differ 13: 355-362, 2002.
18. Leeman RJ, Lui vW and Grandis JR: STAT3 as a therapeutic 
target in head and neck cancer. Expert Opin Biol Ther 6: 231-241, 
2006.
19. Siavash H, Nikitakis NG and Sauk JJ: Abrogation of IL-6-
mediated JAK signalling by the cyclopentenone prostaglandin 
15d-PGJ(2) in oral squamous carcinoma cells. Br J Cancer 91: 
1074-1080, 2004.
20. Lee TL, Yeh J, van Waes C and Chen Z: Epigenetic modification 
of SOCS-1 differentially regulates STAT3 activation in response 
to interleukin-6 receptor and epidermal growth factor receptor 
signaling through JAK and/or MEK in head and neck squamous 
cell carcinomas. Mol Cancer Ther 5: 8-19, 2006.
21. Naher L, Kiyoshima T, Kobayashi I, et al: STAT3 signal trans-
duction through interleukin-22 in oral squamous cell carcinoma. 
Int J Oncol 41: 1577-1586, 2012.
22. Jewett A, Head C and Cacalano NA: Emerging mechanisms of 
immunosuppression in oral cancers. J Dent Res 85: 1061-1073, 
2006.
23. Lai SY and Johnson FM: Defining the role of the JAK-STAT 
pathway in head and neck and thoracic malignancies: impli-
cations for future therapeutic approaches. Drug Resist Updat 13: 
67-78, 2010.
24. Maggioni D, Gaini R, Nicolini G, et al: MAPKs activation in 
head and neck squamous cell carcinomas. Oncol Rev 5: 223-231, 
2011.
25. Johnson GL and Lapadat R: Mitogen-activated protein kinase 
pathways mediated by ERK, JNK, and p38 protein kinases. 
Science 298: 1911-1912, 2002.
26. Pearce AK and Humphrey TC: Integrating stress-response and 
cell-cycle checkpoint pathways. Trends Cell Biol 11: 426-433, 2001.
27. Dunn C, Wiltshire C, MacLaren A and Gillespie DA: Molecular 
mechanism and biological functions of c-Jun N-terminal kinase 
signalling via the c-Jun transcription factor. Cell Signal 14: 
585-593, 2002.
28. Jain N, Zhang T, Fong SL, et al: Repression of Stat3 activity 
by activation of mitogen-activated protein kinase (MAPK). 
Oncogene 17: 3157-3167, 1998.
29. Sengupta TK, Talbot ES, Scherle PA and Ivashkiv LB: Rapid 
inhibition of interleukin-6 signaling and Stat3 activation 
mediated by mitogen-activated protein kinases. Proc Natl Acad 
Sci USA 95: 11107-11112, 1998.
30. Quadros MR, Peruzzi F, Kari C and Rodeck U: Complex regu-
lation of signal transducers and activators of transcription 3 
activation in normal and malignant keratinocytes. Cancer 
Res 64: 3934-3939, 2004.
31. Kovarik P, Stoiber D, Eyers PA, et al: Stress-induced phosphory-
lation of STAT1 at Ser727 requires p38 mitogen-activated protein 
kinase whereas IFN-gamma uses a different signaling pathway. 
Proc Natl Acad Sci USA 96: 13956-13961, 1999.
32. Ahmed ST, Mayer A, Ji JD and Ivashkiv LB: Inhibition of IL-6 
signaling by a p38-dependent pathway occurs in the absence of 
new protein synthesis. J Leukoc Biol 72: 154-162, 2002.
33. Tkach M, Rosemblit C, Rivas MA, et al: p42/p44 MAPK-mediated 
Stat3Ser727 phosphorylation is required for progestin-induced 
full activation of Stat3 and breast cancer growth. Endocr Relat 
Cancer 20: 197-212, 2013.
34. Chen RJ, Ho YS, Guo HR and Wang YJ: Rapid activation of 
Stat3 and ERK1/2 by nicotine modulates cell proliferation in 
human bladder cancer cells. Toxicol Sci 104: 283-293, 2008.
35. Gough D, Koetz L and Levy D: The MEK-ERK pathway is 
necessary for serine phosphorylation of mitochondrial STAT3 
and Ras-mediated transformation. PLoS One 8: e83395, 2013.
36. xue P, Zhao Y, Liu Y, Yuan Q, et al: A novel compound RY10-4 
induces apoptosis and inhibits invasion via inhibiting STAT3 
through ERK-, p38-dependent pathways in human lung adeno-
carcinoma A549 cells. Chem Biol Interact 209: 25-34, 2014.
37. Lee MH, Huang Z, Kim DJ, et al: Direct targeting of MEK1/2 and 
RSK2 by silybin induces cell-cycle arrest and inhibits melanoma 
cell growth. Cancer Prev Res 6: 455-465, 2013.
38. Aguzzi A, Maggioni D, Nicolini G, et al: MAP kinase modu-
lation in squamous cell carcinoma of the oral cavity. Anticancer 
Res 29: 303-308, 2009.
39. Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase 
signalling pathways in cancer. Oncogene 26: 3279-3290, 2007.
40. Chen Z, Gibson TB, Robinson F, et al: MAP kinases. Chem 
Rev 101: 2449-2476, 2001.
41. Lee SH, Lee JW, Soung YH, et al: Colorectal tumors frequently 
express phosphorylated mitogen-activated protein kinase. 
APMIS 112: 233-238, 2004.
42. Mendoza MC, Er EE and Blenis J: The Ras-ERK and PI3K-mTOR 
pathways: cross-talk and compensation. Trends Biochem Sci 36: 
320-328, 2011.
43. Anjum R and Blenis J: The RSK family of kinases: emerging 
roles in cellular signalling. Nat Rev Mol Cell Biol 9: 747-758, 
2008.
44. Bessard A, Frémin C, Ezan F, et al: RNAi-mediated ERK2 
knockdown inhibits growth of tumor cells in vitro and in vivo. 
Oncogene 27: 5315-5325, 2008.
45. Obajimi O and Melera P: Suppression of ERK1/2 with siRNA 
restores drug sensitivity in DU145 cells selected for resistance to 
AG2034 (abstract 77). Cancer Res 70: (Suppl 1), 2010.
46. Smalley KS: A pivotal role for ERK in the oncogenic behaviour 
of malignant melanoma? Int J Cancer 104: 527-532, 2003.
47. Gao J, Zhao Y, Lv Y, et al: Mirk/Dyrk1B mediates G0/G1 to 
S phase cell cycle progression and cell survival involving MAPK/
ERK signaling in human cancer cells. Cancer Cell Int 13: 2, 2013.
48. Balmanno K and Cook SJ: Tumour cell survival signalling by the 
ERK1/2 pathway. Cell Death Differ 16: 368-377, 2009.
49. Lin YC, Wu MH, Wei TT, et al: Degradation of epidermal 
growth factor receptor mediates dasatinib-induced apoptosis 
in head and neck squamous cell carcinoma cells. Neoplasia 14: 
463-475, 2012.
GKOUvERIS et al:  ERK1/2 AND STAT3 SIGNALING IN ORAL CANCER2182
50. Ji WT, Chen HR, Lin CH, et al: Monocyte chemotactic 
protein 1 (MCP-1) modulates pro-survival signaling to promote 
progression of head and neck squamous cell carcinoma. PLoS 
One 9: e88952, 2014.
51. Wang L, Liu T, Nishioka M, et al: Activation of ERK1/2 and 
cyclin D1 expression in oral tongue squamous cell carcinomas: 
relationship between clinicopathological appearances and cell 
proliferation. Oral Oncol 42: 625-631, 2006.
52. Bancroft CC, Chen Z, Dong G, et al: Coexpression of proan-
giogenic factors IL-8 and vEGF by human head and neck 
squamous cell carcinoma involves coactivation by MEK-MAPK 
and IKK-NF-kappaB signal pathways. Clin Cancer Res 7: 
435-442, 2001.
53. Duvvuri U, Shiwarski DJ, xiao D, et al: TMEM16A induces 
MAPK and contributes directly to tumorigenesis and cancer 
progression. Cancer Res 72: 3270-3281, 2012.
54. Li B, Lu L, Zhong M, Tan xx, et al: Terbinafine inhibits KSR1 
and suppresses Raf-MEK-ERK signaling in oral squamous cell 
carcinoma cells. Neoplasma 60: 406-412, 2013.
55. Lavoie JN, L'Allemain G, Brunet A, et al: Cyclin D1 expression 
is regulated positively by the p42/p44MAPK and negatively by 
the p38/HOGMAPK pathway. J Biol Chem 271: 20608-20616, 
1996.
56. Zhao Y, Lv M, Lin H, et al: Rho-associated protein kinase 
isoforms stimulate proliferation of vascular smooth muscle cells 
through ERK and induction of cyclin D1 and PCNA. Biochem 
Biophys Res Commun 432: 488-493, 2013.
57. Si H, Peng C, Li J, Wang x, et al: RNAi-mediated knockdown 
of ERK1/2 inhibits cell proliferation and invasion and increases 
chemosensitivity to cisplatin in human osteosarcoma U2-OS 
cells in vitro. Int J Oncol 40: 1291-1297, 2012.
58. Dumesic PA, Scholl FA, Barragan DI and Khavari PA: Erk1/2 
MAP kinases are required for epidermal G2/M progression. J 
Cell Biol 185: 409-422, 2009.
59. Judd NP, Winkler AE, Murillo-Sauca O, et al: ERK1/2 regulation 
of CD44 modulates oral cancer aggressiveness. Cancer Res 72: 
365-374, 2012.
60. Katada K, Tomonaga T, Satoh M, et al: Plectin promotes migration 
and invasion of cancer cells and is a novel prognostic marker 
for head and neck squamous cell carcinoma. J Proteomics 75: 
1803-1815, 2012.
61. Zuo JH, Zhu W, Li MY, et al: Activation of EGFR promotes 
squamous carcinoma SCC10A cell migration and invasion via 
inducing EMT-like phenotype change and MMP-9-mediated 
degradation of E-cadherin. J Cell Biochem 112: 2508-2517, 
2011.
62. Li R, You S, Hu Z, et al: Inhibition of STAT3 by niclosamide 
synergizes with erlotinib against head and neck cancer. PLoS 
One 8: e74670, 2013.
63. Wakahara R, Kunimoto H, Tanino K, et al: Phospho-Ser727 of 
STAT3 regulates STAT3 activity by enhancing dephosphory-
lation of phospho-Tyr705 largely through TC45. Genes Cells 17: 
132-145, 2012.
64. Hazan-Halevy I, Harris D, Liu Z, Liu J, et al: STAT3 is consti-
tutively phosphorylated on serine 727 residues, binds DNA, and 
activates transcription in CLL cells. Blood 115: 2852-2863, 2010.
65. Sakaguchi M, Oka M, Iwasaki T, et al: Role and regulation of 
STAT3 phosphorylation at Ser727 in melanocytes and melanoma 
cells. J Invest Dermatol 132: 1877-1885, 2012.
66. Miyakoshi M, Yamamoto M, Tanaka H and Ogawa K: 
Serine 727 phosphorylation of STAT3: an early change in mouse 
hepatocarcinogenesis induced by neonatal treatment with dieth-
ylnitrosamine. Mol Carcinog 53: 67-76, 2014.
67. Wierenga AT, vogelzang I, Eggen BJ and vellenga E: Erythro-
poietin-induced serine 727 phosphorylation of STAT3 in 
erythroid cells is mediated by a MEK-, ERK-, and MSK1-
dependent pathway. Exp Hematol 31: 398-405, 2003.
68. Nelson EA, Walker SR, Kepich A, et al: Nifuroxazide inhibits 
survival of multiple myeloma cells by directly inhibiting STAT3. 
Blood 112: 5095-5102, 2008.
69. Sumimoto H, Imabayashi F, Iwata T and Kawakami Y: The 
BRAF-MAPK signaling pathway is essential for cancer-immune 
evasion in human melanoma cells. J Exp Med 203: 1651-1656, 
2006.
